The%20Sixth%20RTD%20Framework%20Programme%202002-2006 - PowerPoint PPT Presentation

View by Category
About This Presentation
Title:

The%20Sixth%20RTD%20Framework%20Programme%202002-2006

Description:

Life Sciences: Genomics ... Focussing and integrating Community research: 7 Thematic ... diseases, GA9-Neurosciences, KA6-Ageing population) ... – PowerPoint PPT presentation

Number of Views:28
Avg rating:3.0/5.0
Slides: 46
Provided by: RTDF
Learn more at: http://tigma.archimedes.ee
Category:

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: The%20Sixth%20RTD%20Framework%20Programme%202002-2006


1
The Sixth RTD Framework Programme 2002-2006
  • Thematic Priority 1
  • Life Sciences Genomics Biotechnology for
    Health
  • http//europa.eu.int/comm/research/fp6/index_en.ht
    ml
  • http//www.cordis.lu/fp6/

2
(No Transcript)
3
Focussing and integrating Community research 7
Thematic priorities


  • Budget (million )
  • 1. Life sciences genomics biotechnology
  • for health
    2,255
  • 2. Information society technologies 3,625
  • 3. Nanotechnologies nanosciences. 1,300
  • 4. Aeronautics space 1,075
  • 5. Food quality safety 685
  • 6. Sustainable development, global change
  • and ecosystems
    2,120
  • 7. Citizens and governance.
    225

4
TP1. Life sciences genomics biotechnology for
health
Why focus on genomics ?
? Sequencing of human genome (and other
genomes) ? Major opportunity to improve human
health ? Stimulus for business activity ? Needs
to transform mass of raw data into useful
knowledge ? To be competitive with US and Japan,
we need to have a coordinated approach at the
European level for many topics in genomics. ? EU
will invest by scientific interest and for
avoiding to become a client
Integration with other approaches ?
Multidisciplinarity
5
TP1. Life sciences genomics biotechnology for
health
First call expected 17 December 2002 Deadline 25
March 2003
Thematic priority 1. First call Work
programme Illustrations only! focusing on
Networks of Excellence and Integrated Projects
6
TP1. Life sciences genomics biotechnology for
health
Funding instruments
New (inclusion of new partners during project
life-time) - Networks of Excellence - Integrated
Projects Traditional - Specific Targeted
Research Projects (STREP) - Co-ordination actions
(CA) - Specific Support Actions (SSA) Also dont
miss other opportunities (including fellowships)
across the whole Sixth Framework Programme!
7
TP1. First call indicative budget
Total budget for first call 513 million,
broken down as follows Instrument
(million) Integrated project or network of
excellence 385 410 Specific targeted research
project or co-ordination action 92 121
Specific support actions 8
10
8
TP1. First call indicative budget


15 of FP Thematic Priorities budget is for
participation of small and medium sized
enterprises (SMEs) Specific activities
Co-operative research carried out by
research centres for SMEs or by high- tech SMEs
in collaboration with research centres and
universities Collective research carried
out by research centres for industrial
associations or industry groupings in entire
sectors of industry dominated by SMEs
9
TP1. Life sciences genomics biotechnology for
health
i. Advanced genomics and its applications for
health ( 1,100 m)
a. Fundamental knowledge and basic tools for
functional genomics in all organisms (FP5
Generic Activities, Research into Genomes and
diseases of genetic origin)
b. Application of knowledge and technologies in
the field of genomics and biotechnology for
health (FP5 Key Action 3, The Cell Factory
10
TP1. Life sciences genomics biotechnology for
health
ii. Combating major diseases ( 1,155 m)
a. Applications- oriented genomic approaches to
medical knowledge and technologies (FP5
GA 7-Chronic and degenerative diseases, diabetes,
cardiovascular diseases and rare diseases,
GA9-Neurosciences, KA6-Ageing population)
b. Combating cancer (FP5 GA7)
c. Confronting the major communicable diseases
linked to poverty (AIDS, tuberculosis,
malaria) (FP5 KA2 Control of Infectious Diseases)
11
TP1. Life sciences genomics biotechnology for
health
Expressions of Interest
  • Report on the analysis of expressions of interest
    2002
  • Thematic priority 1
  • Genomics and biotechnology for health
  • http//www.cordis.lu/fp6/eoi-analysis.htm
  • Potential topics that could be used for first and
    subsequent calls of FP6
  • To help potential participants become familiar
    with the new instruments

12
TP1. Life sciences genomics biotechnology for
health
i. Advanced genomics and its
applications for health a. Fundamental
knowledge and basic tools for functional genomics
in all organisms to foster basic understanding
of genomic information, by developing the
knowledge base, tools and resources needed to
decipher the function of genes and gene products
relevant to human health
- Gene expression and proteomics - Structural
genomics - Comparative genomics and population
genetics - Bioinformatics - Multidisciplinary
functional genomics approaches to basic
biological processes
13
TP1. Indicative topics/ instruments for first
call
  • Gene expression and proteomics
  • (2 topics in first call) (1 indicative topic for
    next call(s))
  • Developing high throughput tools and approaches
    for monitoring gene expression and protein
    profiles and for determining protein function and
    protein interactions
  • Development of advanced array technologies
    (IP/NoE)
  • - for the analysis, with high precision and
    sensitivity, of large sets of proteins, DNA and
    RNA and for functional cell arrays
  • Technology development

14
TP1. Indicative topics/ instruments for first call
  • Structural genomics (3) (2)
  • Developing high throughput approaches for
    determining
  • high-resolution 3-D structures of
    macromolecules.
  • Development of new hardware and software for
    the implementation of innovative automated
    technologies at synchrotron sites (IP)
  • - developing, assembling, standardising and
    providing highly integrated and automated
    technological platforms at synchrotron research
    centres for high throughput structural genomics
  • Specific and ambitious objectives
  • Infrastructures can be part of IP and NoE

15
TP1. Indicative topics/ instruments for first call
  • Comparative genomics and population
  • genetics (2) (4)
  • Developing model organisms and transgenic tools
    developing epidemiology tools and standardised
    genotyping protocols.
  • Integrated tools for functional genomics of
    non- mammalian vertebrate models for human
    development and disease mechanisms (IP)
  • - develop and use high throughput tools,
    technologies and approaches . for harvesting
    large data sets on gene functions...
  • Model organisms to complement the integrated
    project on mouse functional genomics (funded by
    the QoL programme in FP5)

16
TP1. Indicative topics/ instruments for first call
  • Bioinformatics (1) (2)
  • Developing bioinformatics tools and resources
    for data storage, mining and processing
    developing computational biology approaches for
    in silico prediction of gene function and for the
    simulation of complex regulatory networks.
  • Developing methods and resources in
    bioinformatics to focus on the annotation of
    human and other genomes (NoE)
  • - cooperation between life scientists and
    bioinformaticians to coordinate the design
    and development of new integrated
    bioinformatics tools and approaches...
  • Structuring the field - life scientists
    bioinformaticians
  • Spreading excellence

17
TP1. Indicative topics/ instruments for first call
  • Multidisciplinary functional genomics
  • approaches to basic biological processes (7) (8)
  • Elucidation of the mechanisms underlying
    fundamental cellular processes, to identify the
    genes involved and to decipher their biological
    functions in living organisms.
  • Integrated comparative and functional genomics
    approaches for studying the cell cycle (IP/ NoE)
  • - multidisciplinary functional genomics
    approaches in different model organisms for
    elucidating .. Basic mechanisms controlling the
    cell cycle
  • Basic knowledge - wide implications in health
    research

18
TP1. Indicative topics/ instruments for first call
  • Multidisciplinary functional genomics approaches
    to basic biological processes (continued)
  • Multidisciplinary approaches of functional
    genomics to study chronic inflammation
    processes in human disease (NoE)
  • - co-ordination of research activities
  • Specific diseases can be addressed ..but the
    emphasis should be on basic mechanisms
  • Basic mechanisms - implications in many diseases

19
TP1. Indicative topics/ instruments for first call
  • Research areas - 1st call - STREP/CA/SSA
  • transcription activation, signal transduction,
    intra-cellular communication, the role of
    non-coding genomic information, mechanisms of
    integration of genes
  • in silico prediction of gene function and
    simulation of complex regulatory networks
  • development of new tools and approaches,
    including the standardisation of protocols, to
    facilitate generation of new knowledge in
    functional and structural genomics

20
TP1. Indicative topics/ instruments for first call
  • 1. Advanced genomics and its applications to
    health
  • b. Applications of knowledge and technologies in
    the field of genomics and biotechnology for
    health
  • to foster the competitiveness of Europes
    biotechnology industry
  • the integration of small and medium sized
    enterprises (SMEs) in projects is essential

21
TP1. Indicative topics/ instruments for first call
Technological platforms for developments in the
fields of new diagnostic, prevention and
therapeutic tools - New, safer, more effective
drugs, pharmacogenomics approaches (4) (3) -
New diagnostics (1) (2) - New in vitro tests to
replace animals (1) (1) - New preventive and
therapeutic tools (e.g. stem cells,
immunotherapies) (3) (6) - Innovative
post-genomic research with high potential for
application (2) (4)
22
TP1. Indicative topics/ instruments for first call
  • New, safer, more effective drugs,
  • pharmacogenomics approaches (4)(3)
  • translation of the knowledge and methods derived
    from genomics into concrete applications for drug
    design and development
  • Genome-based individualised medicines (NoE)
  • - structuring of efforts devoted to
    characterisation of drug targets.. to optimise
    individual drug selection, dosage and delivery
    .. to improve the benefit / risk ratio of drugs
  • Cooperation of research and clinical centres,
    ethical bodies, regulatory authorities,
    healthcare providers, pharmaceutical industry

23
TP1. Indicative topics/ instruments for first call
  • New diagnostics (1)(2)
  • early diagnosis, monitoring of disease
    progression and interpretation of in-vivo data
  • Non-invasive diagnostics and diagnostic
    procedures development of markers for ante-
    and neo-natal screening (NoE)
  • - structuring of efforts devoted to development
    of non- invasive tools for pre-natal diagnosis
    and the translation of genomics data into
    diagnostic applications.
  • Translational research cooperation of academia,
    ethical bodies, regulatory authorities,
    pharmaceutical industry

24
TP1. Indicative topics/ instruments for first call
  • New in vitro tests to
  • replace animal experimentation (1)(1)
  • Directive 86/609/EEC  regarding the protection
    of animals used for experimental and other
    scientific purposes
  • Combination and application of in vitro cell and
    sensor technologies in the field of animal in
    vivo toxicology (IP)
  • - research should focus on in vitro cell-based
    toxicological and pharmacological tests for
    screening drug compounds
  • Technology development

25
TP1. Indicative topics/ instruments for first call
  • New preventative and
    therapeutic tools (3)(6)
  • integration of different research activities in
    genetics, fundamental and clinical research and
    ethics to provide standardised research materials
    such as stem cell banks, clinical research
    protocols and novel preventive and therapeutic
    instruments at a European level.
  • New advances in cell-based therapies for the
    regeneration of connective tissue (IP)
  • - application of mesenchymal stem cell research,
    gene transfer and tissue engineering for the
    treatment of connective tissue diseases..
    defining quality and safety standards for
    tissue regeneration ... leading to new
    biological implants capable of functional load
    bearing
  • Several disciplines involved
  • Industry, regulatory authorities

26
TP1. Indicative topics/ instruments for first call
  • Post-genomics with high application
    potential (2)(4)
  • use cutting edge technologies in a
    multidisciplinary approach to address areas of
    research that will benefit from the developments
    resulting from genomics
  • Plant platforms for immunotherapeutic
    biomolecule production (IP)
  • - focus on pharmaceuticals (vaccines, other
    immunotherapeutics) for which a plant-based
    production system offers real advantage and
    potential
  • Appropriate participation of developing
    countries
  • Experimental design to minimise ecological impact

27
TP1. Indicative topics/ instruments for first call
Research areas - 1st call - STREP/CA/SSA New
drugs targeting G-protein coupled receptors
through pharmacogenomics Educational schemes
utilising interdisciplinary approaches for the
integration of pre-clinical and clinical research
(e.g. training events, workshops) Development of
novel non-invasive and repeatable diagnostics
using bioinformatic tools New diagnostic tools
for prion associated diseases
28
TP1. Indicative topics/ instruments for first call
Research areas - 1st call -
STREP/CA/SSA Technology foresight meeting on
test development, validation and
implementation Workshop on business
opportunities in pharmaceutical
toxicology Partnership event on the development
and manufacture of toxicology test methods for
regulatory testing needs Forum on the
achievements in raising awareness on the use of
alternative methods in Candidate Countries
29
TP1. Life sciences genomics biotechnology for
health
ii. Combating major diseases
  • a. Applications- oriented genomic approaches to
    medical knowledge and technologies
  • - Cardiovascular disease, diabetes, rare diseases
  • - Resistance to antibiotics and other drugs
  • - Brain and combating diseases of the nervous
    system
  • - Human development and the ageing process

30
TP1. Life sciences genomics biotechnology for
health
ii. Combating major diseases
  • a. Applications- oriented genomic approaches to
    medical knowledge and technologies
  • to develop improved strategies for the prevention
    and management using also advanced technologies
    for health - of human disease and for living and
    ageing healthily
  • integrate a genomic approach through all relevant
    organisms into more established medical
    approaches for investigating disease and health
    determinants
  • translational research aimed at bringing basic
    knowledge through to clinical application

31
TP1. Indicative topics/ instruments for first call
  • Cardiovascular, diabetes, rare diseases
    (6)(4)
  • Integrating clinical expertise and resources with
    relevant model systems and advanced tools in
    functional genomics gtgt breakthroughs in
    prevention and disease management
  • Pool Europes research resources to tackle rare
    diseases
  • Genomics of heart muscle development and disease
    (NoE)
  • - durable integration of researchers working
    on nor-mal/abnormal development of the heart
    translation of new knowledge to the treatment of
    complications of heart disease (heart failure,
    arrhythmias)
  • Child health congenital cardiovascular
    malformation

32
TP1. Indicative topics/ instruments for first call
  • Resistance to antibiotics and other drugs
    (2)(4)
  • Exploitation of knowledge of microbial genomes
    and host- pathogen interactions gtgt vaccines,
    alternative strategies
  • Strategies for optimal use of antimicrobials
  • Support EC network on epidemiological
    surveillance and control of communicable
    diseases.
  • Testing anti-viral drug resistance and
    understanding resistance development (IP or NoE)
  • - setting up a broad approach towards testing
    and following up antiviral drug resistance in
    human virus infections. integrate basic,
    clinical, pharmacological, immunological and
    virological research

33
TP1. Indicative topics/ instruments for first call
  • Brain, combating diseases of the nervous system
    (6)(5)
  • use genome information to understand better
    brain function, damage, plasticity and repair,
    learning, memory, cognition in order to gain new
    insight into mental processes, to combat
    neurological disorders and diseases, and to
    improve brain repair
  • Human brain tissue research (NoE)
  • - research and studies on genetic and
    environmentalinfluences on brain diseases
  • - standardisation of tissue sampling, shared
    use, diagnosis, ethical issues, clinical history,
    genotyping, accessibility and training
  • Infrastructural aspects, structuring the field
  • Spreading excellence

34
TP1. Indicative topics/ instruments for first call
  • Human development and the ageing process
    (2)(4)
  • Human genome sequence, genomic and postgenomic
    research applied to understand human development
    and healthy ageing in order to develop the
    evidence base for improving public strategies and
    to promote healthy living and healthy ageing
  • Genetic factors of longevity and healthy ageing
    (IP/NoE)
  • - to compare health status, family history,
    different age and gender groups, genetic
    background to identify genetic markers and
    expression profiles for the prediction of
    longevity and healthy ageing
  • Population studies, special expertise and
    facilities in Europe

35
TP1. Indicative topics/ instruments for first call
Research areas - 1st call -
STREP/CA/SSA Rare disorders of plasma membrane
transporters for amino-acids, lipids and sugars
Workshop on the structuring of European research
activities to more effectively combat drug
resistant hospital infections Specific brain
research support actions Molecular mechanisms of
bone homeostasis - prevention or treatment of
osteoporosis
36
TP1. Indicative topics/ instruments for first call
ii. Combating major diseases
  • b. Combating cancer (6) (8)
  • Establishing facilities for exploitation of
    research (evidence-based guidelines for good
    clinical practice and improved public health
    strategies), supporting clinical
    research/clinical trials, supporting
    translational reseach
  • Translating basic knowledge of functional
    onco-genomics into cancer diagnosis and treatment
    (IP/NoE)
  • - large-scale analysis to identify signalling
    pathways, oncogenes, tumour supressor genes
  • - epigenetic mechanisms and genomic instability
  • - new molecular targets for anticancer drug
    discovery
  • Translational research

37
TP1. Indicative topics/ instruments for first call
ii. Combating major diseases
  • c. Confronting the major communicable
  • diseases linked to poverty (5) (5)
  • Developing candidate interventions, establishing
    a clinical trials programme, establishing an AIDS
    Therapy Trials Network
  • - HIV/AIDS
  • - malaria
  • - tuberculosis
  • Also European and Developing Countries
    Clinical Trials Partnership (EDCTP) - action
    through Treaty Article 169

38
TP1. Indicative topics/ instruments for first call
  • Additional SSAs to be supported
  • Promotion of SME participation
  • Stimulating international co-operation
  • Linking with Candidate Countries
  • Stimulating exploitation of research results
    stemming from past and present EU programmes
  • Realising ERA objectives activities such as
    pilot initiatives on benchmarking, cartography,
    networking, the debate on human values and
    technology options, or the collective management
    of the knowledge infrastructures of the future,
    etc
  • EU Strategy for Life Sciences and Biotechnology.
    Action Plan attached to COM(2002)27
  • Supporting future research policy development

39
TP1. First call
EC contribution ? Integrated project Rough
estimate 10-15 million - but higher
possible (compare QoL integrated projects in FP5)
http//europa.eu.int/comm/research/fp6/pdf/ip_pro
visions_111102final.pdf Network of excellence
(examples) 100 researchers, 25 PhD students
ca 10.5 million 200 researchers, 50 PhD
students ca 18.5 million http//europa.eu
.int/comm/research/fp6/pdf/noe_111102final.pdf
40
TP1. First call
How many integrated projects/ network of
excellence will be funded for the first call in
TP1? 53 topics to be published in the
call Budget available for IP or NoE 385
410 million Therefore, competition between
proposals for the same topic, as well as between
topics Some topics may not be funded
41
TP1. First call
  • Indicative schedule
  • First call published 17 December 2002
  • First deadline (25) March 2003
  • Other tentative deadlines
  • November 2003 November 2004 November 2005

42
  • Other FP6 actions
  • related to Life Sciences (health)
  • ERA-NET
  • Supporting the cooperation and coordination of
    research activities carried out at national or
    regional level
  • Health of key groups (major diseases, rare
    diseases, poverty-related diseases,
    alternative/non-conventional medicine)
  • http//europa.eu.int/comm/research/fp6/era-net.htm
    l
  • http//europa.eu.int/comm/research/fp6/pdf/11385-2
    _en.pdf

43
  • Other FP6 actions
  • related to Life Sciences (health)
  • Anticipating science and technology needs
  • (Priority 8 - FP5 GA10-11)
  • Research responding to health policy
    requirements
  • implementation of the European Social Agenda
  • public health and consumer protection
  • Health determinants, provision of high quality
    and sustainable health care services (ageing,
    demographic change)
  • Public health issues, including epidemiology for
    disease prevention
  • Impact of environmental issues on health
  • Handicapped / disabled people

44
Other FP6 actions related to Life
Sciences (health) TP2. Information society
technologies bioinformatics data handling
communication TP3. Nanotechnologies
nanobiotechnology clean technologies
nanodevices for drug delivery biosensors tissue
regeneration biomaterials (FP5 Growth and QoL
KA3) TP5. Food quality and safety
nutrition plant and animal biotech food
diseases and allergies GMO traceability
functional food pathogenic microorganisms BSE
(FP5 QoL KA1 4) TP6. Sustainable development
and global change renewable energies marine and
terrestrial biodiversity and ecosystems (FP5
EESD)
45
TP1. Life sciences genomics biotechnology for
health
Further Information
Fundamental genomics manuel.hallen_at_cec.eu.int
Applied genomics biotech
alfredo.aguilar-romanillos_at_cec.eu.int Major
diseases alain.vanvossel_at_cec.eu.int Cancer
maria-jose.vidal-ragout_at_cec.eu.int Poverty
related diseases arnd.hoeveler_at_cec.eu.int Res
earch related to structuring / strengthening ERA
timothy.hall_at_cec.eu.int
About PowerShow.com